Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GI NEUMEGA HAS "MODEST" BENEFIT IN REDUCING CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA -- FDA REVIEWER; LABEL SHOULD CAUTION ABOUT VOLUME EXPANSION

Executive Summary

Therapy with Genetics Institute's Neumega at the recommended dose sought by the company led to a 28% platelet transfusion avoidance rate compared to 7% for placebo, Center for Biologics Evaluation & Research reviewer Richard Steffen, MD, told FDA's Biological Response Modifiers Advisory Committee July 24.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS030573

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel